Ong Ye Kung, Singapore’s Minister of Health, announced the opening of the first five JTVCs on Tuesday (May 24). Novavax’s Nuvaxovid COVID-19 immunization has been booked by over 2,600 persons in Singapore. Mr. Ong stated that the Novavax vaccine was beneficial to “those who are not suitable for mRNA immunization.”
Novavax is a game-changer for two reasons: For starters, because it employs older technology, it can assist people who are skeptical of mRNA immunizations or have been cautioned against them. Recent Novavax trials have revealed fewer and less significant side effects, implying faster shot recovery. This may encourage people who are unable to miss work to be immunized.
Novavax’s mRNA vaccines are based on “older, more familiar science” than Pfizer and Moderna’s (part of the vaccines administered to children).
The vaccine is created by inserting a gene for Covid-19’s modified spike protein into a virus.
Mr. Ong stated that Singapore has placed an advance order for the vaccine and expected it to arrive in 2021.
On June 14, 2021, Novavax revealed that the vaccine was 93.2 percent effective against Covid-19 concerns and interests, and 100 percent effective against other Covid-19 versions. It was 91 percent effective in high-risk populations.
Overall vaccination efficacy is 90.4 percent, which is “better” than the industry average.
The JTVCs can provide up to 4,500 vaccinations and 2,000 ART/PCR tests per day, according to Mr. Ong’s piece, and five more will be available by the end of next month.
“As of May 23, 130 patients had received their first dose of the primary series, and 550 had been boosted with Nuvaxovid.” As of lunchtime, 2,600 people had made appointments for immunization.
“Let’s be safe,” wrote Ong.